MX2015016065A - Metodos para predecir y mejorar la supervivencia de pacientes de cancer colorrectal. - Google Patents

Metodos para predecir y mejorar la supervivencia de pacientes de cancer colorrectal.

Info

Publication number
MX2015016065A
MX2015016065A MX2015016065A MX2015016065A MX2015016065A MX 2015016065 A MX2015016065 A MX 2015016065A MX 2015016065 A MX2015016065 A MX 2015016065A MX 2015016065 A MX2015016065 A MX 2015016065A MX 2015016065 A MX2015016065 A MX 2015016065A
Authority
MX
Mexico
Prior art keywords
methods
predicting
survival
colorectal cancer
improving
Prior art date
Application number
MX2015016065A
Other languages
English (en)
Inventor
Sharat Singh
Phillip Kim
Anjali Jain
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2015016065A publication Critical patent/MX2015016065A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona ensayos y métodos para predecir la supervivencia de un sujeto que tiene cáncer colorrectal (CCR), determinando de esta manera si el sujeto tendrá un buen pronóstico o mal pronóstico. La presente invención también proporciona ensayos y métodos para predecir la eficacia y/o respuesta terapéutica a terapéuticos anticáncer en un sujeto que tenga CRC, seleccionando de este modo un régimen terapéutico al que sea probable que responda el sujeto.
MX2015016065A 2013-05-21 2014-05-21 Metodos para predecir y mejorar la supervivencia de pacientes de cancer colorrectal. MX2015016065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361825998P 2013-05-21 2013-05-21
PCT/IB2014/061606 WO2014188363A1 (en) 2013-05-21 2014-05-21 Methods for predicting and improving the survival of colorectal cancer patients

Publications (1)

Publication Number Publication Date
MX2015016065A true MX2015016065A (es) 2016-03-21

Family

ID=50896377

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016065A MX2015016065A (es) 2013-05-21 2014-05-21 Metodos para predecir y mejorar la supervivencia de pacientes de cancer colorrectal.

Country Status (10)

Country Link
US (1) US9903867B2 (es)
EP (2) EP3373010A1 (es)
JP (1) JP6478417B2 (es)
KR (1) KR20160009070A (es)
AU (1) AU2014269946A1 (es)
CA (1) CA2912989A1 (es)
HK (1) HK1223156A1 (es)
MX (1) MX2015016065A (es)
SG (1) SG11201509367RA (es)
WO (1) WO2014188363A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102332655B1 (ko) * 2020-05-18 2021-11-30 고려대학교 산학협력단 대장암 예후 예측용 마커 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532138A (en) 1990-04-26 1996-07-02 Behringwerke Ag Method and kits for determining peroxidatively active catalysts
US5332662A (en) 1992-07-31 1994-07-26 Syntex (U.S.A.) Inc. Methods for determining peroxidatively active substances
ATE177842T1 (de) 1993-09-03 1999-04-15 Behringwerke Ag Fluoreszenz-sauerstoffkanalisation-immunteste
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
CA2521106A1 (en) * 2003-04-01 2004-10-14 Monogram Biosciences, Inc. Intracellular complexes as biomarkers
EP2064549B1 (en) 2006-09-21 2012-10-24 Prometheus Laboratories, Inc. Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
AU2008276251B2 (en) 2007-07-13 2014-04-24 Nestec S.A. Drug selection for lung cancer therapy using antibody-based arrays
NZ600339A (en) 2008-02-25 2013-12-20 Nestec Sa Drug selection for breast cancer therapy using antibody-based arrays
US8396228B2 (en) 2008-02-27 2013-03-12 Stethoscope Technologies, Inc. Floating ballast mass active stethoscope or sound pickup device
US8137919B2 (en) * 2008-04-10 2012-03-20 Montefiore Medical Center Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib
NZ616755A (en) 2009-05-14 2015-05-29 Nestec Sa Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
AU2010310746B2 (en) 2009-10-20 2015-07-23 Nestec S.A. Proximity-mediated assays for detecting oncogenic fusion proteins
US20120231965A1 (en) * 2011-02-03 2012-09-13 Prometheus Laboratories Inc. Drug selection for colorectal cancer therapy using antibody-based arrays
EP2681552A2 (en) * 2011-03-02 2014-01-08 Nestec S.A. Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures

Also Published As

Publication number Publication date
KR20160009070A (ko) 2016-01-25
EP2999966A1 (en) 2016-03-30
EP2999966B1 (en) 2018-04-25
EP3373010A1 (en) 2018-09-12
JP6478417B2 (ja) 2019-03-06
JP2016520198A (ja) 2016-07-11
US20160169898A1 (en) 2016-06-16
SG11201509367RA (en) 2015-12-30
HK1223156A1 (zh) 2017-07-21
AU2014269946A1 (en) 2015-12-03
US9903867B2 (en) 2018-02-27
WO2014188363A1 (en) 2014-11-27
CA2912989A1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
PH12015502565A1 (en) Anti-transferrin receptor antibodies and methods of use
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
GB2545361A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
EP2971132A4 (en) FABRIC AND BLOOD-BASED MIRNA BIOMARKERS FOR THE DIAGNOSIS, FORECASTING AND PREDICTING THE METASTAS POTENTIAL IN COLOR LECTAL CANCER
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
WO2015017537A3 (en) Colorectal cancer recurrence gene expression signature
MX2016012697A (es) Perfiles de marcadores biologicos de proteina para detectar tumores colorrectales.
MX2015015605A (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.
WO2013188605A3 (en) Predictive markers for cancer and metabolic syndrome
TR201903312T4 (tr) Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.
PH12014502410A1 (en) Breast cancer prognosis, prediction of progesterone receptor subtype and|prediction of response to antiprogestin treatment based on gene expression
MX2021002014A (es) Metodo para determinar el riesgo de recidiva de cancer de mama.
IL245766B (en) Different levels in blood cell samples of emt markers for the diagnosis of cancer, in particular colon cancer (crc) and pancreatic cancer (pc)
WO2013124738A3 (en) Methods and biomarkers for detection and prognosis of cervical cancer
NZ712023A (en) Caix stratification based cancer treatment
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
WO2015077342A3 (en) Detection of arginine methylation of egfr for prediction of resistance to therapy
EP3080299A4 (en) Biomarkers of rapid progression in advanced non-small cell lung cancer
MX2015015015A (es) Metodo para diagnosticar cancer.
EP2972376A4 (en) Methods for determining prognosis of colorectal cancer
WO2014072832A8 (en) Biomarkers for cervical cancer
GB2523693A (en) Materials and methods for determining susceptibility or predisposition to cancer
MX2014012535A (es) Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos.
IN2014DN08312A (es)